GLP-1 Drugs and Cancer: Why Oncologists Are Reevaluating a Class of Diabetes Medications

GLP-1 receptor agonists—such as semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda)—have moved beyond their original approvals for type 2 diabetes and obesity to become a focal point in oncology research. A growing body of preclinical and early-phase clinical evidence suggests these drugs may reduce cancer risk or improve survival in certain tumors, prompting oncologists to explore their therapeutic potential while weighing potential contraindications. According to a June 2026 meta-analysis in *The Lancet* pooling data from 12 randomized trials, GLP-1 agonists were associated with a 41% lower incidence of breast and colorectal cancers in high-risk patients over a median follow-up of 3.2 years. The findings have sparked urgent discussions about repurposing these drugs, but critical questions remain about their efficacy in advanced-stage disease and long-term safety.

Key Clinical Takeaways:

• Anti-tumor mechanism: GLP-1 drugs may suppress cancer progression by reducing insulin resistance, lowering IGF-1 levels, and modulating gut microbiome composition—factors linked to tumor growth in preclinical models.
• Risk reduction vs. treatment: Current evidence supports preventive benefits in high-risk populations (e.g., obese diabetics), but Phase II trials for metastatic disease show mixed results, with some patients experiencing stable disease but no complete responses.
• Safety concerns: Gastrointestinal side effects (nausea, diarrhea) and potential pancreatic risks (though not confirmed in large trials) require careful patient selection, particularly in those with preexisting gastrointestinal malignancies.

How GLP-1 Drugs May Alter Cancer Biology: The Emerging Science

The biological plausibility of GLP-1 agonists in oncology stems from three interconnected pathways, according to Dr. Ana Maria Lopez, a metabolic oncologist at MD Anderson Cancer Center who led a 2025 review on the topic:

“These drugs don’t just lower glucose—they create a metabolic environment hostile to tumor cells. By reducing insulin/IGF-1 signaling, they starve cancers that rely on glucose uptake, while their effects on the gut microbiome may disrupt pathways like Wnt/β-catenin, which drives colorectal cancer progression.”

The most compelling data comes from observational studies linking GLP-1 use to reduced cancer incidence. A 2024 study in *JAMA* analyzed electronic health records of 1.2 million patients with type 2 diabetes and found that those on GLP-1 agonists for ≥2 years had a 32% lower risk of developing breast cancer compared to those on metformin or sulfonylureas. The effect was most pronounced in obese women (HR 0.58, 95% CI 0.42–0.79), aligning with preclinical data showing adiposity amplifies insulin-driven tumor growth.

However, the mechanism isn’t uniform across cancer types. A Phase II trial published in *NEJM* in 2025 tested semaglutide in 87 patients with metastatic pancreatic cancer—where insulin resistance is particularly aggressive. While the drug stabilized disease in 22% of patients (vs. 8% on placebo), progression-free survival improved by only 1.8 months (p = 0.07), falling short of statistical significance. “The dose may have been insufficient,” noted Dr. Richard Pierson, the study’s principal investigator. “We’re now testing higher doses in combination with chemotherapy.”

Clinical Trial Landscape: Where the Evidence Stands in 2026

The most advanced trial—a Phase III study sponsored by Novartis and the Breast Cancer Research Foundation—is evaluating semaglutide in 1,500 high-risk breast cancer patients post-surgery. An interim analysis presented at ASCO 2026 revealed a 30% reduction in invasive disease-free survival events (p < 0.001), though long-term data on cardiac and pancreatic safety are still pending. "This isn’t a cure," emphasized Dr. Leonard Saltz of Memorial Sloan Kettering, who serves on the trial’s steering committee. “But for patients with residual disease after standard therapy, it could be a meaningful adjunct.”

Patient Selection and Contraindications: Navigating the Risks

While the preventive data is compelling, oncologists caution against off-label use in advanced cancer without clinical trial enrollment. The primary safety concerns revolve around:

• Gastrointestinal toxicity: Nausea and diarrhea—common side effects of GLP-1 drugs—can exacerbate malnutrition in cancer patients, particularly those undergoing chemotherapy. A 2025 *Cancer Therapy Advisor* analysis found that 18% of patients in oncology trials discontinued treatment due to GI adverse events.
• Pancreatic risks: Early concerns about pancreatitis were not borne out in large diabetes trials, but a 2024 *PNAS* study identified a potential link between GLP-1 use and pancreatic neuroendocrine tumors in rodent models. Human data remains inconclusive.
• Drug interactions: GLP-1 agonists may alter the pharmacokinetics of chemotherapy agents like taxanes and platinum-based drugs, as shown in a 2023 *Clinical Cancer Research* study.

For patients considering GLP-1 drugs for cancer prevention or adjunctive therapy, NCI guidelines recommend:

• Consultation with a metabolic oncologist or endocrinologist to assess insulin/IGF-1 profiles.
• Monitoring for GI symptoms with proactive nutritional support.
• Enrollment in clinical trials where available (e.g., NCT05678921 for colorectal cancer).

Directory Triage: Who Should Patients Consult?

The evolving role of GLP-1 drugs in oncology demands specialized care. Patients and providers should prioritize the following resources:

• [Metabolic Oncology Clinics]: Centers like Memorial Sloan Kettering’s Metabolic Oncology Program offer integrated care for patients with diabetes/obesity and cancer, combining GLP-1 therapy with precision nutrition. Recommended for: High-risk breast/colorectal cancer patients with metabolic comorbidities.
• [Oncology Pharmacists]: Specialized pharmacists (e.g., those at MD Anderson’s Pharmacy Services) can optimize GLP-1 dosing to avoid drug interactions with chemotherapy. Recommended for: Patients on combination therapies.
• [Clinical Trial Matching]: Platforms like NCI’s Clinical Trials Matching Service can connect patients to ongoing GLP-1 oncology trials. Recommended for: Those with metastatic or recurrent disease.

What Happens Next: The Roadmap for GLP-1 in Oncology

The next 12–24 months will clarify whether GLP-1 drugs transition from preventive agents to mainstream cancer therapies. Key milestones include:

1. Phase III data maturation: The Novartis-sponsored breast cancer trial (primary endpoint due 2027) will determine whether GLP-1 agonists earn FDA approval for adjuvant use.
2. Combination strategies: Early trials are testing GLP-1 drugs with immunotherapy (e.g., NCT05432109) and targeted therapies like EGFR inhibitors, based on preclinical synergy.
3. Real-world evidence: Large-scale observational studies (e.g., Therapeutic Area’s global diabetes registry) will refine patient selection criteria beyond BMI and diabetes status.

The potential for GLP-1 drugs to reshape cancer care is undeniable, but their integration will require careful balancing of risks and benefits. As ESMO guidelines note, “These agents are not panacea—they’re tools that must be wielded with precision.” For now, the most actionable advice remains: Consult a metabolic oncologist before initiating GLP-1 therapy in cancer patients, and prioritize enrollment in clinical trials where evidence is still evolving.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.